Full Press Release Details
plc Global Organization
plc Global Organization
contained herein including, without limitation, statements containing
"believes," "anticipates,"
"intends," "expects" and words of similar import,
forward-looking statements concerning the Company's
performance, financial condition and prospects. Because such statements
involve known and unknown risks and
uncertainties, actual results may differ
materially from those
expressed or implied by such forward-looking
these uncertainties, prospective investors are
place undue reliance on such forward-looking
Company undertakes no obligation to publicly update or
any forward-looking statements, whether as a result of
information, future events or otherwise.
Tufts Centre for Study of Drug Development
Market Environment with...
Spending Growth Trend 6%- 8% p.a.
pipelines strengthening
activity & funding in Biotech / Speciality
projects, where CROs are engaged, complete faster than
Biotech Funding continuing to grow,
growth in the number of
with active clinical projects, .
companies running clinical projects
Centre for Drug Evaluation & Research
active INDs for Therapeutic Biological Products Transferred from CBER
effective 10/01/2003
INDs for Therapeutic Biological Products Transferred from CBER to
good recent growth in original IND
which has lead to significant growth in the
R&D Focus, Dec 2006 and previous year SMRs
46% Growth Phase I - II
is enriching pipelines generally,
the Therapeutic Biological Products Transferred from CBER to CDER effective
Centre for Drug Evaluation & Research
re-emergence of growth in NDA applications.
" Pig in a Python", rather a .
Wins - Last 10 Quarters ($ millions)
business wins have led to ..
Net New Business Wins
and strong book-to-bill
to record total backlog levels
backlog forecast to be earned in next 4 quarters
of next 4 quarters forecast revenues
strong forecast coverage of next 4 quarters
a broadening of the customer base.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
Strategy is Organic Growth, with acquisitions
new services or scale.
plc Global Organization
| Q4 '06 | Q4 'PY | % Increase | ||
| Net Revenue | 128.9 | 88.1 | 46.4% | |
| Direct Costs | 72.5 | 48.7 | 48.8% | |
| SG & A | 37.6 | 26.8 | 40.3% | |
| D & A | 3.9 | 3.5 | 11.2% | |
| _____ | _____ | _____ | ||
| Operating Income | 14.9 | 9 | 65% | |
| Net Income | 12.4 | 7 | 79% | |
| _____ | _____ | _____ | ||
| EPS (ex SFAS123R) | 42c | 24c | 75% | |
| EPS (Inc SFAS123R) | 39c | |||
| Weighted Average no. of Shares (ex SFAS123R) | 29.7m | 28.5m |
| FY 2006 | FY 2005 | % Increase | ||
| Net Revenue | 456 | 342.8 | 32.9% | |
| Direct Costs | 254 | 189.6 | 34% | |
| SG & A | 134.7 | 108.5 | 24.1% | |
| D & A | 14.9 | 13.9 | 7.4% | |
| _____ | _____ | _____ | ||
| Operating Income | 51.9 | 30.8 | 68.6% | |
| Net Income | 42.4 | 24.3 | 74.3% | |
| _____ | _____ | _____ | ||
| EPS (ex SFAS123R) | 145c | 86c | 68.6% | |
| EPS (Inc SFAS123R) | 133c | |||
| Weighted Average no. of Shares | 29.3m | 28.3m |
Revenue CAGR of 29% over 7 Years
| May 31, 05 (Year) | Dec 31, 05 (7 mths) | Dec 31, 06 (Year) | |
| Net Cash | $78.4 | $82.3 | $98 |
| Total assets | $347.6 | $349.1 | $476.3 |
| Shareholder's equity | $233.1 | $241.6 | $302.7 |
| Cashflow from operations | $23.8 | $11.7 | $51.5 |
| Capital expenditures | $15.6 | $7.8 | $12.3 |
| Shares outstanding | 27.8 | 28.0 | 28.5 |
Balance Sheet and Cash Flow
Growth v Peers: Net Revenue
between 2000 and 2005
plc Global Organization
Clinical Research is a global provider of outsourced Phase
to the pharmaceutical, biotechnology and medical
management services include:
Medical Writing & Safety Surveillance
(patient registries, health economics, outcomes
Technologies (IVRS, ePRO, Portals, etc.)
(Gross minus Cancelled, Declined, Non Award, Sent to Other
Research 2003 - 2006 Annual (Gross vs. Net)
(Gross minus Cancelled, Declined, Non Award, Sent to Other
Research 2003 - 2006 Annual (Gross vs. Net)
RFP Value ($ Million)
Participating Region
on Award Notification Date
Value not used as 2003-2005 data would not be
Historical Awards by Originating Region
on Award Notification Date
Value not used as 2003-2005 data would not be
Historical Awards by Participating Region
Values by Therapeutic Area Summary